Treatment for EGFR-Mutant Lung Cancer After Progression on EGFR TKI

Download this brief slideset on treatment options for patients with advanced EGFR-mutated NSCLC whose disease has progressed on first-line EGFR TKI therapy.
Helena A. Yu, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 947 KB
Released: November 19, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Adagrasib shows early encouraging activity in patients with KRAS G12C-mutant NSCLC and active, untreated CNS metastases, from Clinical Care Options (CCO) coverage of ASCO 2022

Released: June 13, 2022

Phase II NADIM II trial evaluating neoadjuvant nivolumab plus chemotherapy for resectable stage IIIA/B NSCLC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings